{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:24:08Z","timestamp":1787045048961,"version":"build-2736575974"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["RMHP"],"DOI":"10.2147\/rmhp.s632004","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:25:11Z","timestamp":1787041511000},"page":"1-16","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness Analysis of Ivonescimab Plus Chemotherapy versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer in China Based on the HARMONi-6 Trial"],"prefix":"10.2147","volume":"Volume 19","author":[{"given":"Feng","family":"Xuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minguang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoze","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8]]},"container-title":["Risk Management and Healthcare Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/118410","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/118410","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:25:12Z","timestamp":1787041512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/cost-effectiveness-analysis-of-ivonescimab-plus-chemotherapy-versus-ti-peer-reviewed-fulltext-article-RMHP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/rmhp.s632004","relation":{},"ISSN":["1179-1594"],"issn-type":[{"value":"1179-1594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}